Qyuns Therapeutics Co., Ltd. (QYUNS-B) executed an on-market repurchase of 8,000 H shares on 7 July 2026 at HKD 15.70 per share, spending HKD 0.13 million. All repurchased shares were retained as treasury stock.

Following the transaction, outstanding shares (excluding treasury shares) declined by 0.0036 % to 223.37 million. Treasury shares increased to 3.70 million, while the company’s total issued share count remained unchanged at 227.07 million.

The buyback forms part of the mandate approved on 29 May 2026, which authorises repurchases of up to 22.44 million shares. To date, QYUNS-B has repurchased 0.99 million shares under this mandate, equivalent to 0.44 % of issued shares at the time of approval. In accordance with Hong Kong listing regulations, the company is restricted from issuing new shares or disposing of treasury shares until 6 August 2026.

Board Secretary and Joint Company Secretary Hu Yanbao confirmed that the repurchase complied with Main Board Rule 10.06 and that no material changes have been made to the previously filed explanatory statement.